Lanean...
ACS Chemical Neuroscience Molecule Spotlight on Saredutant
[Image: see text] Saredutant (SR48968), a potentially novel treatment option for major depressive disorders (MDD) and generalized anxiety disorder (GAD), is a drug from Sanofi-Aventis currently in phase III clinical trials. MDD is a common mental disorder that affects 121 million people worldwide, n...
Gorde:
| Egile nagusia: | |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Chemical Society
2010
|
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3368631/ https://ncbi.nlm.nih.gov/pubmed/22776916 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/cn100061r |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|